A severe case of haemodynamic instability during anidulafungin administration. (3rd April 2013)

• Record Type: Journal Article
• Authors: Fink, M.; Zerlauth, U.; Kaulfersch, C.; Rab, A.; Alberer, D.; Preiss, P.; Sternad‐Klobschauer, K.; Habernig, E.; Wandschneider, W.; Grimm, G.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 38:Number 3(2013:Jun.)
• Page Start: 241
• Page End: 242
• Publication Date: 2013-04-03
• Subjects: Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12046
• Languages: English
• ISSNs: 0269-4727

Abstract

<abstract abstract-type="main" id="jcpt12046-abs-0001"> <title>Summary</title> <sec id="jcpt12046-sec-0001" sec-type="section"> <title>What is known and objective</title> <p>Anidulafugin is an echinocandin used for the treatment of candida infections in non‐neutropenic adults. Echinocandins show few drug–drug interactions and are usually well tolerated. We report a case of acute hypotension, bradycardia and haemodynamic instability with consecutive cardiopulmonary resuscitation during anidulafungin administration.</p> </sec> <sec id="jcpt12046-sec-0002" sec-type="section"> <title>Case summary</title> <p>A 41‐year‐old man ICU patient received anidulafungin for a suspected <italic>Candida glabrata</italic> infection. During the first administration of the drug, he developed acute haemodynamic instability with hypotension and bradycardia. The infusion was discontinued immediately and cardiopulmonary resuscitation was performed successfully. The patient regained haemodynamic stability.</p> </sec> <sec id="jcpt12046-sec-0003" sec-type="section"> <title>What is new and conclusion</title> <p>To the authors' knowledge, this is the first report of a life‐threatening adverse event due to haemodynamic instability during anidulafungin administration. Cardiac toxicity associated with echinocandins has been described. Further studies seem to be mandatory to investigate this potential risk.</p> </sec> </abstract>